Get started
Author

Emma Leach

Observed names: E. Leach, Emma L Leach, Emma L. Leach, Leach, Emma L.
Observed institutions: Providence Health Care, University of British Columbia, Simon Fraser University, Immunocore (United Kingdom), BC Children's Hospital, B.C. Women's Hospital & Health Centre
ORCID: 0000-0002-2831-092X
Observed ORCID: 0000-0002-2831-092X
OpenAlex ID: A5044773629
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma
2020 · Mark R. Middleton, Cheryl McAlpine, et al. · Clinical Cancer Research · 281
PDF
Treatable inborn errors of metabolism presenting as cerebral palsy mimics: systematic literature review
2014 · Emma L Leach, Michael Shevell, et al. · Orphanet Journal of Rare Diseases · 105
PDF
Imagination in human social cognition, autism, and psychotic-affective conditions
2016 · Bernard Crespi, Emma Leach, et al. · Cognition · 93
The imprinted gene LRRTM1 mediates schizotypy and handedness in a nonclinical population
2014 · Emma L Leach, Gratien Prefontaine, et al. · Journal of Human Genetics · 51
Episodic ataxia associated with a de novo SCN2A mutation
2016 · Emma L. Leach, Clara D.M. van Karnebeek, et al. · European Journal of Paediatric Neurology · 33
Enrichment of loss-of-function and copy number variants in ventricular cardiomyopathy genes in ‘lone’ atrial fibrillation
2020 · Julieta Lazarte, Zachary W Laksman, et al. · EP Europace · 27
PDF
Molecular Autopsy Implicates Primary Carnitine Deficiency in Sudden Unexplained Death and Reversible Short QT Syndrome
2019 · Roselle Gélinas, Emma Leach, et al. · Canadian Journal of Cardiology · 21
The Evolutionary Biology of Human Neurodevelopment
2015 · Bernard Crespi, Emma Leach · Wiley eBooks · 21
Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer
2025 · Esra Güç, Agatha Treveil, et al. · Nature Communications · 20
Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific
2025 · Joseph J. Sacco, Peter Kirk, et al. · Cell Reports Medicine · 19
How do Physicians Decide to Refer Their Patients for Psychiatric Genetic Counseling? A Qualitative Study of Physicians’ Practice
2016 · Emma Leach, Emily Morris, et al. · Journal of Genetic Counseling · 17
PDF
Schizotypy, cognitive performance, and genetic risk for schizophrenia in a non-clinical population
2013 · Emma L. Leach, Peter L. Hurd, et al. · Personality and Individual Differences · 13
Cascade testing for inherited arrhythmia conditions: Experiences and attitudes of family communication approaches for a Canadian cohort
2022 · Amy Ho, Emma Leach, et al. · Journal of Genetic Counseling · 12
Abstract 517: Tebentafusp induces transient systemic inflammation and modifies the micro-environment to sensitize uveal melanoma tumors to cytotoxic CD8 cells
2021 · Marcus O. Butler, Sarah Stanhope, et al. · Cancer Research · 10
868 Overall survival on tebentafusp in metastatic uveal melanoma (mUM) across the range of tumor gp100 expression levels
2021 · Emma Leach, Sarah Stanhope, et al. · Journal for ImmunoTherapy of Cancer · 4
PDF
571 IL-2 combination with ImmTAC overcomes CD163+ TAM-like M2 macrophage inhibition of ImmTAC-mediated T cell killing of tumor cells
2021 · Rahul Khanolkar, Revashnee Naidoo, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
Abstract 1673: Uveal melanoma study patients with low CD163:CD3 ratio in tumor biopsy and low serum IL-6 showed enhanced tumor shrinkage (TS) and overall survival (OS) on tebentafusp
2021 · Jessica C. Hassel, Adel Benlahrech, et al. · Cancer Research · 3
Abstract LB510: Low baseline macrophage to T cell ratio is predictive of overall survival with tebentafusp in a phase 3 trial in metastatic uveal melanoma
2022 · Sophie Piperno-Neumann, Sarah Stanhope, et al. · Cancer Research · 2
The clinical utility of procainamide‐induced late potentials on the signal averaged ECG
2021 · Charles Michael Pearman, Jagdeep Walia, et al. · Pacing and Clinical Electrophysiology · 2
959 Tebentafusp controls disease and prolongs survival by increasing the T cell: tumor cell ratio, activating T cells and inhibiting tumor proliferation in metastatic uveal melanoma patients
2025 · Adel Benlahrech, James Clubley, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Abstract 1529: Development of lymphoid aggregates in metastatic uveal melanoma tumors treated with tebentafusp
2024 · Takami Sato, Camille Britton-Rivet, et al. · Cancer Research · 1
30 Molecular features associated with long survival on tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial
2023 · Marlana Orloff, Kevin Kim, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Development of lymphoid aggregates in metastatic uveal melanoma (mUM) tumors treated with tebentafusp
2025 · T. Sato, C. Britton-Rivet, et al. · EJC Skin Cancer
PDF
Tumor microenvironment (TME) features and serum cytokines in patients with metastatic uveal and cutaneous melanoma treated with tebentafusp
2024 · O. Hamid, A. Shoushtari, et al. · EJC Skin Cancer
PDF
Supplementary Data from Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma
2023 · Mark R. Middleton, Cheryl McAlpine, et al.
Works count: 31
Citation count: 740
H-index: 12
I10-index: 14
Year
Topic
Type